EA202191939A1 - Химерные антигенные рецепторы gprc5d и экспрессирующие их клетки - Google Patents
Химерные антигенные рецепторы gprc5d и экспрессирующие их клеткиInfo
- Publication number
- EA202191939A1 EA202191939A1 EA202191939A EA202191939A EA202191939A1 EA 202191939 A1 EA202191939 A1 EA 202191939A1 EA 202191939 A EA202191939 A EA 202191939A EA 202191939 A EA202191939 A EA 202191939A EA 202191939 A1 EA202191939 A1 EA 202191939A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- receptors
- gprc5d
- expressing
- cells
- chimeric antigenic
- Prior art date
Links
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 title 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
В настоящем изобретении предложены химерные антигенные рецепторы (CAR), которые специфически нацелены на связанный с G-белком рецептор, семейство С связанных с G-белком рецепторов, группа 5, член D (GPRC5D), и иммунореактивные клетки, содержащие такие CAR, для лечения рака.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962793973P | 2019-01-18 | 2019-01-18 | |
PCT/IB2020/050310 WO2020148677A1 (en) | 2019-01-18 | 2020-01-15 | Gprc5d chimeric antigen receptors and cells expressing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191939A1 true EA202191939A1 (ru) | 2021-10-12 |
Family
ID=69191097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191939A EA202191939A1 (ru) | 2019-01-18 | 2020-01-15 | Химерные антигенные рецепторы gprc5d и экспрессирующие их клетки |
Country Status (21)
Country | Link |
---|---|
US (1) | US20200231686A1 (ru) |
EP (1) | EP3911677A1 (ru) |
JP (2) | JP7303314B2 (ru) |
KR (1) | KR20210116562A (ru) |
CN (1) | CN113597433A (ru) |
AR (1) | AR119676A1 (ru) |
AU (1) | AU2020209257A1 (ru) |
BR (1) | BR112021013824A2 (ru) |
CA (1) | CA3127025A1 (ru) |
CL (1) | CL2021001883A1 (ru) |
CO (1) | CO2021010075A2 (ru) |
EA (1) | EA202191939A1 (ru) |
EC (1) | ECSP21060675A (ru) |
IL (1) | IL284744A (ru) |
JO (1) | JOP20210194A1 (ru) |
MX (1) | MX2021008652A (ru) |
PE (1) | PE20211977A1 (ru) |
SG (1) | SG11202107708XA (ru) |
TW (1) | TW202043263A (ru) |
UY (1) | UY38546A (ru) |
WO (1) | WO2020148677A1 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL299894A (en) * | 2020-07-17 | 2023-03-01 | Janssen Biotech Inc | Anti-idiotypic antibodies against anti-GPRC5D antibodies |
WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
AU2022201736B2 (en) | 2021-01-05 | 2023-03-16 | Lanova Medicines Development Co., Ltd. | Anti-GPRC5D monoclonal antibodies and uses thereof |
US20220267438A1 (en) * | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
CN115386010A (zh) * | 2021-05-23 | 2022-11-25 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
EP4347650A1 (en) * | 2021-06-01 | 2024-04-10 | Janssen Biotech, Inc. | Anti-idiotypic antibodies against anti-cd79b antibodies |
CA3228414A1 (en) * | 2021-09-02 | 2023-03-09 | Anthony DANIYAN | Anti-cd33 antibodies and uses thereof |
WO2023079494A1 (en) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
TW202334222A (zh) * | 2021-11-05 | 2023-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 結合gprc5d的抗體及其用途 |
WO2023173272A1 (zh) * | 2022-03-15 | 2023-09-21 | 上海驯鹿生物技术有限公司 | 靶向gprc5d的全人源嵌合抗原受体(car)及其应用 |
WO2023125728A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 抗gprc5d抗体及其应用 |
WO2023125888A1 (zh) * | 2021-12-31 | 2023-07-06 | 山东先声生物制药有限公司 | 一种gprc5d抗体及其应用 |
WO2023134718A1 (zh) * | 2022-01-14 | 2023-07-20 | 原启生物科技(上海)有限责任公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
WO2023227062A1 (en) * | 2022-05-27 | 2023-11-30 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
WO2024017362A1 (zh) * | 2022-07-22 | 2024-01-25 | 上海先博生物科技有限公司 | 靶向gprc5d和/或bcma的嵌合抗原受体及其应用 |
US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
CN116003598B (zh) * | 2022-08-30 | 2024-04-26 | 苏州缔码生物科技有限公司 | 靶向人gprc5d的重组人源化单克隆抗体及其应用 |
CN116751310B (zh) * | 2023-06-13 | 2024-02-13 | 广东省第二人民医院(广东省卫生应急医院) | 靶向cd19和gprc5d配体的嵌合抗原受体及其应用 |
CN117229407B (zh) * | 2023-11-14 | 2024-02-20 | 成都优赛诺生物科技有限公司 | 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用 |
CN117700558B (zh) * | 2024-02-06 | 2024-05-03 | 苏州艾凯利元生物科技有限公司 | 一种单克隆抗gprc5d抗体和抗gprc5d-car-nk细胞 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
WO2009085462A1 (en) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
SG184427A1 (en) | 2010-04-20 | 2012-11-29 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
WO2013063419A2 (en) * | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
AU2015357518B2 (en) * | 2014-12-05 | 2021-10-07 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof |
AU2016297605A1 (en) * | 2015-07-21 | 2018-02-15 | City Of Hope | T cells for expression of chimeric antigen receptors and other receptors |
US10776517B2 (en) * | 2016-06-10 | 2020-09-15 | OneTrust, LLC | Data processing systems for calculating and communicating cost of fulfilling data subject access requests and related methods |
TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
KR20190133160A (ko) * | 2017-02-07 | 2019-12-02 | 다이이찌 산쿄 가부시키가이샤 | 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자 |
US20190092818A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
EP3887507A1 (en) * | 2018-11-30 | 2021-10-06 | Janssen Biotech, Inc. | Gamma delta t cells and uses thereof |
US20220267438A1 (en) * | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
-
2020
- 2020-01-15 AU AU2020209257A patent/AU2020209257A1/en active Pending
- 2020-01-15 SG SG11202107708XA patent/SG11202107708XA/en unknown
- 2020-01-15 BR BR112021013824A patent/BR112021013824A2/pt unknown
- 2020-01-15 JO JOP/2021/0194A patent/JOP20210194A1/ar unknown
- 2020-01-15 CA CA3127025A patent/CA3127025A1/en active Pending
- 2020-01-15 CN CN202080022394.4A patent/CN113597433A/zh active Pending
- 2020-01-15 US US16/743,188 patent/US20200231686A1/en active Pending
- 2020-01-15 EA EA202191939A patent/EA202191939A1/ru unknown
- 2020-01-15 JP JP2021541185A patent/JP7303314B2/ja active Active
- 2020-01-15 PE PE2021001193A patent/PE20211977A1/es unknown
- 2020-01-15 WO PCT/IB2020/050310 patent/WO2020148677A1/en unknown
- 2020-01-15 EP EP20701897.9A patent/EP3911677A1/en active Pending
- 2020-01-15 KR KR1020217025965A patent/KR20210116562A/ko active Search and Examination
- 2020-01-15 MX MX2021008652A patent/MX2021008652A/es unknown
- 2020-01-16 TW TW109101459A patent/TW202043263A/zh unknown
- 2020-01-17 AR ARP200100123A patent/AR119676A1/es unknown
- 2020-01-17 UY UY0001038546A patent/UY38546A/es unknown
-
2021
- 2021-07-11 IL IL284744A patent/IL284744A/en unknown
- 2021-07-15 CL CL2021001883A patent/CL2021001883A1/es unknown
- 2021-07-29 CO CONC2021/0010075A patent/CO2021010075A2/es unknown
- 2021-08-17 EC ECSENADI202160675A patent/ECSP21060675A/es unknown
-
2023
- 2023-06-22 JP JP2023102126A patent/JP2023130380A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3127025A1 (en) | 2020-07-23 |
SG11202107708XA (en) | 2021-08-30 |
AU2020209257A1 (en) | 2021-08-05 |
JP2023130380A (ja) | 2023-09-20 |
IL284744A (en) | 2021-08-31 |
ECSP21060675A (es) | 2021-09-30 |
KR20210116562A (ko) | 2021-09-27 |
JP2022518708A (ja) | 2022-03-16 |
BR112021013824A2 (pt) | 2021-12-14 |
PE20211977A1 (es) | 2021-10-05 |
TW202043263A (zh) | 2020-12-01 |
CN113597433A (zh) | 2021-11-02 |
UY38546A (es) | 2020-07-31 |
AR119676A1 (es) | 2022-01-05 |
JP7303314B2 (ja) | 2023-07-04 |
MX2021008652A (es) | 2021-10-26 |
JOP20210194A1 (ar) | 2023-01-30 |
WO2020148677A1 (en) | 2020-07-23 |
CL2021001883A1 (es) | 2022-01-21 |
EP3911677A1 (en) | 2021-11-24 |
CO2021010075A2 (es) | 2021-08-19 |
US20200231686A1 (en) | 2020-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202191939A1 (ru) | Химерные антигенные рецепторы gprc5d и экспрессирующие их клетки | |
CL2021000479A1 (es) | Métodos de preparación de células que expresan receptores de antígenos quiméricos | |
CO2019013614A2 (es) | Dominio de unión a antígeno | |
EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
PE20190622A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
CO2019013654A2 (es) | Receptores de antígenos quiméricos que se dirigen a flt3 | |
MX2017013080A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
EA202091982A1 (ru) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии | |
PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
JOP20210326A1 (ar) | أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها | |
MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
MX2021011750A (es) | Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos. | |
CU20180129A7 (es) | Anticuerpos anti-basigin humanizados | |
PE20221273A1 (es) | Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos | |
MX2021003636A (es) | Receptor antigenico quimerico. | |
PE20220217A1 (es) | Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso | |
MX2021012488A (es) | Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos. | |
MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
MX2020010092A (es) | Variantes de anticuerpo c-terminales. | |
MX2022004712A (es) | Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5. |